News Details
National Comprehensive Cancer Network Shares New Recommendations for Treating Children with Brain Tumors
Newly-published NCCN Guidelines for Pediatric Central Nervous System Cancers synthesize latest evidence to help care teams ensure children with high-grade gliomas have best possible outcomes; available free at NCCN.org.
PLYMOUTH MEETING, PA [July 12, 2022] — Today, the National Comprehensive Cancer Network® (NCCN®) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Central Nervous System (CNS) Cancers. This is now the fifth current NCCN Guidelines® to focus on childrens’ cancers, following recent publications of evidence-based, expert consensus guidelines for Pediatric Acute Lymphoblastic Leukemia, Pediatric Aggressive Mature B-Cell Lymphomas, Pediatric Hodgkin Lymphoma, and Wilms Tumors. Though rare, pediatric brain tumors are the second-most-common type of pediatric malignancy after leukemia and are the leading cause of cancer-related death in children.[1] [2]
“I think about these families and everything they go through, and I know we’re going to keep working every day to make things better for them,” said Anita Mahajan, MD, Mayo Clinic, Vice-Chair of the NCCN Guidelines Panel for Pediatric CNS Cancers. “These NCCN Guidelines, covering high-grade gliomas, are an important start. They consolidate the complicated information that’s needed across interdisciplinary teams, including pediatric oncologists/neuro-oncologists, pediatric radiation oncologists, pathologists, and pediatric neurosurgeons, so they are all ready to work together to provide the most effective diagnosis and treatment.”
Dr. Mahajan continued: “We’re planning to expand the guidelines to include other CNS tumor types. Right now, the science is advancing as we learn more about how to differentiate and characterize these tumors. In the future, with more trial results coming in, we anticipate an increase in personalized medicine with treatments targeted to the specific patient and tumor.”
The World Health Organization recently updated their classifications for central nervous system tumors, with a new structure specifically focused on pediatric CNS tumors. This fundamental paradigm shift in classification is reflected and explained in the NCCN Guidelines for Pediatric CNS Cancers.
“Treating children with cancer is very different from adults, particularly for CNS tumors. We need to be extra careful to not impact physical and cognitive development and to protect against long term side-effects,” explained NCCN Guidelines for Pediatric CNS Cancers Panel Chair Amar Gajjar, MD, Chair of the Department of Pediatrics, St. Jude Children’s Research Hospital. “For instance, radiation is a key component when treating adults, but options to avoid or reduce radiation in young children are important, especially those under age 3. These guidelines provide a snapshot of how leading experts from across the country are applying the current evidence to recommend the best approach for infants, young children, and adolescents into early adulthood. We’re committed to update these guidelines at least once a year moving forward.”
NCCN intends to cover at least 90% of all incident childhood cancers through the growing library of NCCN Guidelines for pediatric cancers. The adult guidelines provide comprehensive management recommendations for 97% of all incident cancer in the United States and globally, as well as screening, prevention, and supportive care, including survivorship best practices. There are also NCCN Guidelines for Specific Populations, including recommendations for how to optimally tailor care in adolescent and young adult (AYA) patients.
Previously-published NCCN Guidelines for Pediatric ALL have also been adapted into a version for patients and caregivers, harmonized for resource-constrained settings, and translated into Chinese, French, Indonesian, Italian, Japanese, Portuguese, Russian, and Spanish.
“We want to do whatever we can to ease the burden of cancer on children and their families and make sure every child can get the best care possible,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN Guidelines have a proven track record for improving cancer outcomes and are a trusted source of information for care providers all over the world. We are proud to advance care by providing everyone with access to the very latest recommendations from some of the top experts in the field.”
NCCN Guidelines can be viewed and downloaded free-of-charge for non-commercial use at NCCN.org or via the NCCN Virtual Library of NCCN Guidelines® app.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.
[1] Pfister SM, Reyes-Mugica M, Chan JKC, et al. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discov 2022;12:331-355.
[2] American Cancer Society. Cancer Facts and Figures 2022. 2022. Available at: https://www.cancer.org/latest-news/facts-and-figures-2022.html. Accessed April 26, 2022.